ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 76.35 USD | +0.73% |
|
+1.57% | +13.36% |
| May. 03 | Angle shares up on assay development deal with AstraZeneca | AN |
| May. 03 | Angle shares up on assay development deal with AstraZenaca | AN |
Financials (USD)
| Sales 2024 * | 51.18B | Sales 2025 * | 54.8B | Capitalization | 234B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.52B | Net income 2025 * | 10.19B | EV / Sales 2024 * | 4.97 x |
| Net Debt 2024 * | 20.03B | Net Debt 2025 * | 13.54B | EV / Sales 2025 * | 4.52 x |
| P/E ratio 2024 * |
27.9
x | P/E ratio 2025 * |
23.3
x | Employees | 89,900 |
| Yield 2024 * |
2.05% | Yield 2025 * |
2.14% | Free-Float | 96.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More press releases
More news
| 1 day | +0.73% | ||
| 1 week | +1.57% | ||
| Current month | +0.62% | ||
| 1 month | +14.28% | ||
| 3 months | +16.32% | ||
| 6 months | +19.37% | ||
| Current year | +13.36% |
1 week
75.32
76.80
1 month
66.8976.80
Current year
60.4776.80
1 year
60.4776.80
3 years
52.6576.80
5 years
36.1576.80
10 years
25.5576.80
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 13-01-31 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.38% | 9 M€ | -4.31% | - | |
| 0.99% | 1,182 M€ | +1.22% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 76.35 | +0.73% | 9,026,349 |
| 24-05-02 | 75.8 | -0.80% | 10,038,808 |
| 24-05-01 | 76.41 | +0.70% | 4,911,684 |
| 24-04-30 | 75.88 | +0.53% | 8,547,408 |
| 24-04-29 | 75.48 | +0.41% | 7,538,322 |
Delayed Quote Nasdaq, May 03, 2024 at 04:15 pm EDT
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
151.2
USD
Average target price
164.5
USD
Spread / Average Target
+8.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B | |
| -3.40% | 157B | |
| +1.72% | 123B |
- Stock Market
- Equities
- AZN Stock
- AZN Stock
